Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Hypomethylating agents in MDS and AML

David Sallman • 28 May 2020
ASCO 2020
Acute Myeloid Leukemia Myelodysplastic Syndromes Azacitidine Decitabine Magrolimab Pevonedistat Venetoclax

David Sallman, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, gives an overview of the use of hypomethylating agents (HMA) in high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from David Sallman

2:08
Hematological response to frontline treatment in LR-MDS is associated with better OS
David Sallman • 9 Dec 2023
1:58
Canakinumab plus darbepoetin in patients with LR-MDS following ESA failure
David Sallman • 9 Dec 2023
2:49
Front-line treatment options for HR-MDS: can we move past azacitidine?
David Sallman • 9 Dec 2023
Transplantation & immunotherapies
Charles Craddock et al. • 4 Sep 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
The content of VJHemOnc is intended for healthcare professionals